Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The synthetic collagen revolution NVH Medicinal Global Expert in Synthetic Collagen NVH Medicinal is a Dijon -based biotechnology company, created at the end of 2008 whose mission is based on the treatment of pathologies linked to a collagen deficit. It develops products derived from collagen, the most abundant protein in the body and whose dysfunctions cause many diseases (aging, cardiovascular, inflammatory, neurological, fibrosis, cancer and rare diseases). NVH's ambition is to be recognized as an innovative player in the treatment of collagen -related diseases by becoming one of the global leaders in the development, production and marketing of a new …

60 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

AGV Discovery offers services in chemistry, cell biology, in vitro screening, rational drug design, outsourcing and consultancy. AGV Discovery is a pharmaceutics that specializes in rational design and early development of drug candidates.

61 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Development of innovative neurological therapeutics based on pannexin channels Panntherapi develops innovative drugs in Neurology by acting on a specific target, the activated pannexin 1 channel, aiming a better efficacy and tolerance than current drugs. Panntherapi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target addressing the root cause of the diseases - Representative non-clinical model using among others ex vivo human brain tissues Biotech, Neurology, Epilepsy, and Deeptech

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Member of the Roche Group Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVERTM Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity.

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the …

55 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your partner in immunology projects! ImmunXperts a Q2 Solutions Company, your partner for what’s next in assay and biomarker development, advanced laboratory testing, and translational immunology. ImmunXperts brings an unrivaled ability to efficiently develop immunogenicity and immuno-oncology in vitro assays – to address both wanted and unwanted immunity for novel modalities. Immunogenicity Assessment, Immune Academy, Training, Consultancy, immuno-oncology, Cell Therapy, In vitro, assay development, Primary cells, Immunogenicity, and Immunology

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

88 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Defy Limits. Deliver Results. Made Scientific is a leading cell therapy contract development and manufacturing organization (CDMO) dedicated to advancing the field of cell therapy. Since 2019, the company has specialized in developing, manufacturing, and releasing autologous and allogeneic cell therapy products for early- to mid-stage clinical trials, and has evolved into an end-to-end clinical-to-commercial service provider. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the flexibility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. CDMO, Process Development, Analytical …

88 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

TriSalus Life Sciences® seeks to transform outcomes for patients with solid tumors TriSalus Life Sciences is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.

138 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sealing The Broken Barrier Currently we are not hiring. Please beware of scammers Artus is a pre-clinical stage company developing first-in-class therapeutics for inflammatory and metabolic diseases by targeting barrier dysfunction.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Research center & amp; Health development Bionoveo offers project leaders, industrial or academic, biological, technical and methodological skills and resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes.

283 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

346 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the power of NIK to transform the future of cancer and autoimmune disease treatment Nikaia Pharmaceuticals, an innovative company dedicated to the discovery and development of cutting-edge therapeutic solutions to improve patients' lives. 🔬💊 Our mission is to push the boundaries of science to deliver novel and effective treatments, focusing on the NIK protein (NF-κB-inducing kinase) and developing molecules capable of blocking its action.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies

56 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

207 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Biomanufacturing services Naobios provides bioprocess development and contract manufacturing services for viral vaccines and viral vectors. The company was acquired by Clean Biologics on March 1st, 2019 and now supports clients for process development and the manufacture of preclinical and clinical batches.

159 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurological disorders. Corlieve Therapeutics, a fully owned subsidiary of UniQure, is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New view for cancer Therapeutic Sirius Neosight is an innovative technological breakdown company which aims to become a key player in the detection of subclashed neo-cancers, relapses and therapeutic monitoring of patients thus offering a new look to doctors on the therapeutic efficiency implemented. Sirius Neosight operates a patented from a patented rupture technology from a consortium of academic laboratory experts in the field.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Turn cancer immunotherapies active in most patient Stimunity is a startup company from Institut Curie which develops bio-pharmaceuticals to treat patients that do not respond to immunotherapy in cancer.

25 similar entities Type: Startup Activities: biotech deeptech

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing healthcare through innovative adenosine receptor-based drugs Palobiofarma S.L. is a Spanish biopharmaceutical company dedicated to discovering and developing innovative drugs based on the modulation of adenosine receptors.

226 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

299 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pionnier de la thérapie régénératrice cardiaque CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans. Heart Regeneration

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ultimate predictability Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Smart Way to Immune Tolerance TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016.

7 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group. Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

13 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

InBrain Pharma, a CNS disorders focused biotech, founded in 2018, exploiting through an exclusive worldwide patent license signed with the Northern France TTO, a groundbreaking therapeutic approach of advanced Parkinson’s Disease based on the research work of Pr David DEVOS and Pr Caroline MOREAU developed within their academic research Team from the Université́ de Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and the Lille University Hospital. To date, the company has raised €4.4 million in dilutive and non-dilutive financing, these funds having enabled to carry out a first phase I/IIb DIVE-I clinical trial on 12 patients, for which results …

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AFTERM is a medicinal chemistry company that develops innovative molecules for therapeutic for cancer and hearing loss, as well as innovative active ingredients in the field of dermo-cosmetics. Playing is a medicinal chemistry company that development innovative therapeutic molecules against cancer and hearing loss, as well as innovative active ingredients in the field of dermo-cosmetics.

67 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

What You See Is What You Seq - Revolutionary cell analysis solution for fundamental, translational & pharma/biotech R&D Minos Biosciences is on the path to bridge molecular and cell biology in a manner never achieved before that will, in turn, allow scientists to uncover the full picture of cell diversity and dynamics. By combining multi-omics analysis with phenotypic analysis at cell resolution and at high throughput, Minos’ solution provides a new paradigm in cell analysis that will open up new frontiers in life science research, precision medicine and diagnostics.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the access to innovative ingredients and APIs thanks to plant biotechnology. STH BIOTECH develops unique and reliable plant-biotech process to unlock the production of rare APIs and innovative botanical ingredients.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative start up developing monoclonal antibodies in cancer and inflammatory diseases MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

114 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI-powered Precision Immunology Scienta Lab is a deeptech company developing a unique and proprietary artificial intelligence technology to transform the drug discovery and development process in immunology and inflammation. Artificial Intelligence, Clinical Trials, and Immunology

120 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I.

Immunotherapy against senescence StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

69 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties. R&D-wise, GeneCode has remarkably improved the properties of the identified hits, making them more active and effective, drug-like and better show their ability to combat neurodegeneration in Parkinson ́s disease (PD).

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeting Chronic Pain Algonist Biotechnologies is a pre-clinical stage biotechnology company, developing novel small molecule therapeutics for chronic pain. Our mission is to develop drugs with similar potency to opioids but without leading to addiction.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Securing your vision Recornea is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the cornea, such as keratoconus, glaucoma and corneal transplants.

84 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBio Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications. contact@partitionbio.co.uk

328 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing the storage and delivery of vaccines and therapeutics. We are a biotechnology company revolutionizing vaccines and biologics by removing all cold storage requirements and expediting manufacturing.

83 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

INNERVATE. SCREEN. PREDICT. NETRI is a technology enabling company that provides human cell based smart assays for high throughput preclinical data acquisition for the neurological Pharma & Cosmetics industries. We provide organs-on-chip solutions & interoperable in vitro models designed to deeply accelerate drug discovery and preclinical trials by mimicking in vivo neural connectivity. neuroscience, microfluidics, neural network, organ on chip, neurofluidics, neurological troubles, Alzheimer, Parkinson, organonchip, dermo-cosmetics, and toxicology

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell Culture Monitoring Instruments IPRASENSE revolutionizes cell analysis with innovative technologies for automated cell counting and real-time visualization, ideal for research and quality control. Cell culture monitoring, Lensless Lensfree Imaging, Video microscopy, Time lapse Imaging, Automatic cell count and viability analysis, High throughput cell, Inside your incubator, cell count, cell counting, cell viability, cell viability analysis , cell monitoring, and angiogenesis

103 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Repair the liver without graft GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation. GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

22 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

marine-inspired molecules to fight immunological diseases Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion. Biotechnologie, immunologie, antibiorésistance, and commotions

69 similar entities Type: Startup Activities: deeptech biotech

Delivering the iPSC platforms that ready the world for next-gen cell therapies Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Dairy Done Differently Imagindairy, a Foodtech company, is addressing the industry bottleneck by integrating deep tech with system biology to develop a commercial and viable animal free protein-based dairy product

93 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Innovation at the service of your health and well-being. Pharmaceutical company, R & AMP; D dedicated to the development and marketing of senolytic compounds, food supplements and aging medications, age -related degenerative diseases and cancer.

322 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

We deliver solutions AdhexPharma is an independent drug delivery company specialized in Transdermal & Topical patches and Oral Thin Films technologies. AdhexPharma is based in France, with GMP manufacturing facility for European and US market. We have 4 approved products in Europe and North America and a pipeline of 6 candidates, ranging from 505(b)2 / NDA and ANDA in different therapeutical areas: pain, CNS, anesthesia, smoking cessation and HRT. Trandermal, Patch, Oral Thin Film, Drug Development, GMP manufacturing, FDA approved, OTF, ODF, cGMP, TDS, CDMO, and CMO

61 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

European Distributor of innovative cell culture products KDBIO is distributing advanced cell culture devices used for producing monoclonal antibodies, and 3D culture plates for generating multiple spheroid replicates per well, as well as 3D culture plates with nanofiber scaffolds. G-Rex culture systems can be purchased from KDBIO in the EU. Distribution, monoclonal antibodies, 3D culture, CAR-T, and Patient-derived spheroids

54 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Treating the untreatable BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Designing and delivering cell therapies to transform the lives of people with cancer. Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

62 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the therapeutic potential of AAT AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.

60 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

70 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Versatile immunotherapy for personalized cancer medicine Inovactis develops an innovative treatment against cancer at the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. personalized immunotherapy and medicine

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biomade Peptides We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

165 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Therapeutics for the Disease of Aging Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases Oncology, Aging, Dark Genome, ALS, Diabetes, and Longevity

198 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

161 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making it possible CLEAN BIOLOGICS is a CDMO for Viral vectors, Viral vaccines and oncolytic viruses and Biosafety testing for biological products. As well as a CMO for MCB & WCB production. GMP compliance

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

264 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Cellvax, founded in 2001, is a preclinical biotech company which provides in vitro and in vivo studies allowing accelera Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products. Preclinical studies CRO, Animal models, Cancer, Osteoarthritis, Bio-markers, …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

375 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

520 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases Vandria is a biopharmaceutical company that develops best-in-class small molecule mitophagy inducers to treat age-related and chronic diseases in the fields of Muscle- and CNS diseases with large unmet medical need.

127 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The IV drug-delivery expert Technoflex is the independent leader in the design, production and commercialization of I.V. drug delivery bags (standard or customized) and connectors with FDA and EMEA references. With a devoted R&D team, Technoflex offers a specific high value opportunity of taylored products to its partners.

59 similar entities Type: SMB Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Plant-based Nanotechnologies for autoimmune diseases diagnoses and therapy DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules. The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications. As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Diamante, thanks to the Regione Veneto and particularly though the national grant POR FESR AZIONE 1.1.1 2020/2021, has …

55 similar entities Type: Startup Activities: nanotech biotech deeptech healthtech Technologies: Synthetic Biology

IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.

46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology